Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;20(2):67-68.
doi: 10.1038/s41575-022-00717-4.

NAFLD, MAFLD and obesity: brothers in arms?

Mariana Verdelho Machado  1   2 , Helena Cortez-Pinto  3
Affiliations

NAFLD, MAFLD and obesity: brothers in arms?

Mariana Verdelho Machado et al. Nat Rev Gastroenterol Hepatol. 2023 Feb.
No abstract available

PubMed Disclaimer

References

    1. Henry, L., Paik, J. & Younossi, Z. M. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment. Pharmacol. Ther. 56, 942–956 (2022). - DOI
    1. Soon, G. & Wee, A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: histological perspective. Clin. Mol. Hepatol. 27, 44–57 (2021). - DOI
    1. Naoumov, N. V. et al. Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. J. Hepatol. 77, 1399–1409 (2022). - DOI
    1. Romero-Gómez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829–846 (2017). - DOI
    1. Gastaldelli, A. et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10, 393–406 (2022). - DOI

MeSH terms

LinkOut - more resources